ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2 Monoclonal Antibody QL1209

Its studies are mostly in Breast Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 3, since Oct 28, 20202 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical21 open or runningphase 3since Oct 28, 2020Oct 28, 2020Apr 2027phase 1 · NCT07861139

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2020First study: phase 3 study in Breast NeoplasmsFirst studyNCT04629846 · 517 enrolled · China
  2. Sep 30, 2026Phase 1 study in Breast NeoplasmsNCT07861139 · 80 planned

Ahead

  1. Apr 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07861139

TargetBeta

ERBB2 →read by rule
“A humanized monoclonal antibody directed against the domain II of the extracellular domain of human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07861139Breast Neoplasms1Not yet recruitingApr 202780
NCT04629846Breast Neoplasms · China3CompletedAug 22, 2022517

How it is read

Names in the registry

  • “QL1209”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.